Compare OMEX & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | CSBR |
|---|---|---|
| Founded | 1986 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 98.5M |
| IPO Year | N/A | 1986 |
| Metric | OMEX | CSBR |
|---|---|---|
| Price | $1.47 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.2M | 5.1K |
| Earning Date | 11-12-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | $467,122.00 | ★ $58,424,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ N/A | $37.71 |
| Revenue Growth | N/A | ★ 9.06 |
| 52 Week Low | $0.27 | $5.59 |
| 52 Week High | $4.43 | $11.98 |
| Indicator | OMEX | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 29.83 | 48.56 |
| Support Level | $2.12 | $6.58 |
| Resistance Level | $1.95 | $7.71 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 0.42 | 30.07 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.